In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study

Multiple Sclerosis

Cerebrospinal fluid biomarkers link toxic astrogliosis and microglial activation to multiple sclerosis severity

Mult Scler Relat Disord.

Masvekar R, Wu T, Kosa P, Barbour C, Fossati V, Bielekova B

doi: 10.1016/j.msard.2018.11.032.

Aging and Cognitive FunctionsAlzheimer’s DiseaseMultiple Sclerosis

Alzheimer disease pathology and the cerebrospinal fluid proteome

Alzheimers Res Ther.

Dayon L, Núñez Galindo A, Wojcik J, Cominetti O, Corthésy J, Oikonomidi A, Henry H, Kussmann M, Migliavacca E, Severin I, Bowman GL, Popp J

doi: 10.1186/s13195-018-0397-4.

Multiple Sclerosis

Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis

J Neurol Neurosurg Psychiatry.

Rathbone E, Durant L, Kinsella J, Parker AR, Hassan-Smith G, Douglas MR, Curnow SJ

doi: 10.1136/jnnp-2018-317947.

Multiple Sclerosis

Soluble CD27 Levels in Cerebrospinal Fluid as a Prognostic Biomarker in Clinically Isolated Syndrome

JAMA Neurol.

van der Vuurst de Vries RM, Mescheriakova JY, Runia TF, Jafari N, Siepman TA, Hintzen RQ

doi: 10.1001/jamaneurol.

Multiple Sclerosis

Cerebrospinal fluid complement system biomarkers in demyelinating disease

Mult Scler.

Zelek WM, Fathalla D, Morgan A, Touchard S, Loveless S, Tallantyre E, Robertson NP, Morgan BP

doi: 10.1177/1352458519887905.

Multiple Sclerosis

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

J Neurol.

Kamm CP, Barin L, Gobbi C, Pot C, Calabrese P, Salmen A, Achtnichts L, Kesselring J, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR).

doi: 10.1007/s00415-019-09563-y.

Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury With Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia

JAMA Oncol.

Cheung YT, Khan RB, Liu W, Brinkman TM, Edelmann MN, Reddick WE, Pei D, Panoskaltsis-Mortari A, Srivastava D, Cheng C, Robison LL, Hudson MM, Pui CH, Krull KR

doi: 10.1001/

Multiple Sclerosis

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis

Mult Scler.

Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, Kappos L, Zipp F, Bittner S

doi: 10.1177/1352458518765666.

Multiple Sclerosis

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci

Pharmacogenomics.

Kulakova O, Bashinskaya V, Kiselev I, Baulina N, Tsareva E, Nikolaev R, Kozin M, Shchur S, Favorov A, Boyko A, Favorova O

doi: 10.2217/pgs-2017-0058.

Related content

Cerebrospinal fluid biomarkers link toxic astrogliosis and microglial activation to multiple sclerosis severity

Alzheimer disease pathology and the cerebrospinal fluid proteome

Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis

Soluble CD27 Levels in Cerebrospinal Fluid as a Prognostic Biomarker in Clinically Isolated Syndrome

Cerebrospinal fluid complement system biomarkers in demyelinating disease

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury With Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci